Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan 1, 2000 In Use
S0146 Peginterferon Alfa-2b Pegintron, Sylatron 20 mcg/mL Immunotherapy Cytokine Interferon No 2001 Jul 1, 2005 Sep 30, 2010 No Longer Used
Q2056 Ciltacabtagene autoleucel CARVYKTI up to 100 million Immunotherapy CAR-T No 2022 Sep 27, 2022 In Use
J9030 Bacillus calmette-guerin BCG Vaccine, Tice BCG 1mg Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jul 1, 2019 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug 28, 2023 In Use
J9031 Bacillus calmette-guerin substrain nice live antigen Theracys, BCG Vaccine Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 1991 Jul 1, 2019 No Longer Used
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
C9083 Amivantamab-vmjw Rybrevant 10mg Immunotherapy Monoclonal Antibody EGFR,MET No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
C9163 Talquetamab Talvey 0.25mg Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 No 2023 Dec 7, 2023 Apr 17, 2024 No Longer Used
J9214 Interferon Alfa-2b Intron A 1 million units Immunotherapy Cytokine Interferon No 1986 Jan 1, 1993 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 Jul 1, 2019 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
C9475 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Apr 1, 2016 In Use
C9021 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Apr 4, 2014 Dec 31, 2014 No Longer Used
J9015 Aldesleukin Proleukin Per single vial (1 vial = 22 million IU) Immunotherapy Cytokine Interleukin-2 No 1992 Oct 1, 1996 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.